Latest News
Harpoon Therapeutics Closes USD 70m Series C Financing
15 November 2018 - - US-based clinical-stage immunotherapy company Harpoon Therapeutics, Inc has closed a USD 70m Series C equity financing, the company said.

OrbiMed served as the lead new investor, along with new investors Cormorant, R...
Generon Receives Investigative New Drug Approval from China SFDA for A-319 to Treat Patients with B Cell Malignancies
15 November 2018 - - Chinese biopharmaceutical company Generon Corp has received approval for the company's Investigational New Drug application from the State Food and Drug Administration of the People's Republic of China to initiate ...
Farxiga Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial, According to AstraZeneca
15 November 2018 - - Anglo-Swedish pharmaceutical company AstraZeneca (OTC: AZNCF) has received positive full results from the DECLARE-TIMI 58 cardiovascular outcomes trial for Farxiga (dapagliflozin), the company said.

The data were pre...
Brooklyn ImmunoTherapeutics Presents Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer
15 November 2018 - - US-based biopharmaceutical company Brooklyn ImmunoTherapeutics presented the clinical results of IRX-2 therapy in resectable breast cancer and head and neck cancer that were presented in an oral presentation at the 2018 annual me...
Arixa Pharmaceuticals Publishes Paper Demonstrating First Oral Prodrug of Avibactam
15 November 2018 - - US-based Arixa Pharmaceuticals, Inc., a developer of oral antibiotics for drug-resistant Gram-negative infections, has published a paper describing the chemistry of its oral prodrug of avibactam, a previously intravenous -only be...